1-溴-3-甲苯氧基-2-丙醇的Jones试剂氧化反应

本文采用易得的1-溴-3-甲苯氧基-2-丙醇(1a,1b和1c)经Jones试剂氧化反应,合成了1-溴-3-(4-甲基苯氧基)-2-丙酮(2a)、1-溴-3-(3-甲基苯氧基)-2-丙酮(2b)、1-溴-3-(2-甲基苯氧基)-2-丙酮(2c)化合物,并研究了这类反应的副产物。反应中,产物均经硅胶柱分离得到,IR,^1HNMR,MS确定其结构。产物酮(2a)、(2b)、(2c)非常不稳定,影响了元素分析的准确测定。     

三苯胺氰基丙烯酸类钕配合物的制备及发光性能

分别以2-氰基-3-(4-(二苯胺)苯基)丙烯酸(TPA-1)、2-氰基-3-(5-(4-(二苯胺)苯基)-噻吩-2-基)丙烯酸(TPA-2)和2-氰基-3-(5’-(4-(二苯胺)苯乙烯基)-[2,2’-联噻吩]-5-基)丙烯酸(TPA-3)为配体合成了3个稀土配合物Nd(L)3·2H2O(L=TPA-1,TPA-2,TPA-3)。采用元素分析、核磁共振氢谱(1H NMR)、红外光谱(IR)对配合物的组成进行了确认。通过紫外-可见吸收光谱和荧光光谱的测定,研究了配体共轭链长度对配合物吸光和发光性能的影响。结果表明:配体共轭链长度的增加有效增大了配合物的摩尔吸光系数,拓宽了配合物的吸光范围。配合物固体粉末近红外发光测试表明,Nd(TPA-1)3·2H2O和Nd(TPA-2)3·2H2O在889,1063和1339 nm处有较强的发射峰,分别归属于Nd(III)4F3/2→4I9/2,4F3/2→4I11/2和4F3/2→4I13/2的特征跃迁。     

间氯苯基锰卟啉-5-氟尿嘧啶配合物的合成及其对癌细胞的抑制活性

合成了4种新5-氟尿嘧啶-卟啉衍生物：5-[3-(2-(5-氟尿嘧啶-1-基)乙氧基)苯基]-10,15,20-三(3-氯苯基)卟啉(1a)、5-[3-(2-(5-氟尿嘧啶-1-基)乙氧基)苯基]- 10,15,20-三(3-氯苯基)锰卟啉(2a)、5-[3-(3-(5-氟尿嘧啶-1-基)丙氧基)苯基]-10,15,20-三(3-氯苯基)锰卟啉(2b)和5-[3-(4-(5-氟尿嘧啶-1-基)丁氧基)苯基]-10,15,20-三(3-氯苯基)锰卟啉(2c),通过UV-Vis、IR、MS及元素分析表征了它们的结构。 用噻唑蓝法（MTT法）测定了化合物2a、2b和2c对人胃癌细胞株BGC-823的抑制活性。 化合物2b的半数抑制浓度IC50为1.34 μmol/L,表明有一定的细胞毒作用。     

若干μ_3-氧桥三核锰(Ⅲ)Schiff碱配合物的研究

用元素分析、电导率、磁化率、热分析、红外光谱和电子光谱等方法对新合成的7种μ_3-氧桥三核锰(Ⅲ)Schiff碱配合物:Mn_3O(bzaea)_2(C_2H_3O_2)_3、Mn_3O(bzaea)_2(C_2H_3O_2)_2(NCS)、Mn_3O(bzaea)_3ClO_4·2H_2O、Mn_3O(bzaea)_2(C_2H_3O_2)_2Br、Mn_3O(bzaea)_3I·2H_2O、Mn_3O(bzaea)_2(C_2H_3O_2)_2NO_3和Mn_3O(bzaea)_2(C_2H_3O_2)_2BPh_4·3H_2O(其中bzaea~(2-)是三齿Schiff碱2-(β-羟基乙基-亚胺)-4-苯基-丁酮(4)的负二价阴离子)进行了研究,并提出了配合物的可能构型。     

用BaCl_2反滴定测定SO_4~(2-)的改进

用BaCl_2反滴定测定SO_4~(2-)的方法早有介绍,但是,由于它是在中性溶液中进行测定,多种阴离子如CO_3~(2-)、HCO_3~-、SO_3~(2-)、S_2O_3~(2-)、C_2O_4~(2-)、CrO_4~(2-)、PO_4~(3-)、BO_2~-,SiO_3~(2-)、F~-、MoO_4~(2-)、WO_4~(2-)和阳离子Ca~(2+)、Sr~(2+)、Pb~(2+)等都干扰测定结果。虽经多次改进,仍不够满意。为解决上述问题,我们对配制pH=3.2±0.1的柠檬酸-柠檬酸钠络合缓冲溶液作了初步尝试,得到了较满意的分析结果。试验结果表明:在pH=3的盐酸溶液中,MoO_4~(2-)、C_2O_4~(2-)、     

邻香草醛缩组氨酸Schiff碱及其镧配合物的合成与生物活性

合成了2个新的化合物——邻香草醛缩组氨酸Schiff碱及其镧配合物.通过元素分析、X射线衍射、红外光谱、紫外-可见光谱、热重-差热分析及化学分析等对它们进行了表征.结果表明,邻香草醛缩组氨酸Schiff碱为2-[(2-羟基-3-甲氧基-苯亚甲基)-氨基]-3-(2-咪唑基)-丙酸一水合物(C14H15N3O4·H2O),Schiff碱镧配合物为二氯-{2-[(2-羟基-3-甲氧基-苯亚甲基)-氨基]-3-(2-咪唑基)-丙酸}合镧(Ⅲ)三水合物[La(C14H15N3O4)Cl2·3H2O].应用生物微量热法研究了这2个化合物的生物活性,在301.15 K下测定了2个化合物存在时粟酒裂殖酵母细胞代谢的产热曲线,计算得到了粟酒裂殖酵母细胞生长速率常数(k)、传代时间(tG)、总热效应(Qtotal)、抑制率(I)及半抑制浓度(IC50)等热动力学参数.结果表明,随着C14H15N3O4·H2O和La(C14H15N3O4)Cl2·3H2O浓度的增加,k和Qtotal减小,tG和I增加,IC50分别为0.2585和0.2488mmol/L.     

基于两种柔性同分异构羧酸配体的钴(Ⅱ)配合物的合成、结构及磁性研究(英文)

分别以E-3-[4-(羧甲氧基)-苯基]丙烯酸(H2L1)和E-3-[3-(羧甲氧基)-苯基]丙烯酸(H2L2)为主配体,合成了3种钴(Ⅱ)配位聚合物:[Co(L1)(bpp)]n(1),{[Co(μ3-OH)2(L2)4(bpy)2(H2O)4]·12H2O}n(2)和[Co(L2)(bpy)]n(3)(bpp:1,3-二吡啶基丙烷,bpy:4,4-联吡啶)。通过元素分析、红外光谱、X射线粉末和单晶衍射对其进行了结构表征。结果表明钴(Ⅱ)离子在这3种配合物中具有不同的配位环境,导致3种配合物具有不同的晶体结构和磁性特征。     

单柱离子色谱法测定硒酸根和亚硒酸根的研究

本实验采用单柱离子色谱系统,在SeO_4~(2-)、SeO_3~(2-)与F~-、Cl~-、NO_3~-、SO_4~(2-)离子共存时,以1.0mmol/L邻苯二甲酸氢钾为淋洗液测定了SeO_4~(2-),以1.0mmol/LKNO_3为淋洗液测定了SeO_3~(2-)。SeO_4~(1-)和SeO_3~(2-)的最低检出浓度分别为0.3μg/mL和0.7μg/mL,线性范围分别为0.8～80μg/mL和1.4～150μg/mL,相对标准偏差分别为2.01%和1.85%。并应用本方法测定了加SeO_4~(2-)和SeO_3~(2-)的自来水样,SeO_4~(2-)和SeO_3~(2-)的回收率分别为96%和98%。     

新型不对称酞菁锌的合成和表征

以4-硝基邻苯二甲腈为主要原料,合成了2(3),9(10),16(17),23(24)-四-(正庚酰胺基)-酞菁锌、2(3),9(10),16(17),23(24)-四-(甲氧基)-酞菁锌、2(3),9(10),16(17),23(24)-四-(对叔丁基苯氧基)-酞菁锌和2(3),9(10),16(17),23(24)-四-(苯氧基)-酞菁锌等4种对称型酞菁.在此基础上,选取4-对叔丁基苯氧基邻苯二甲腈为前驱体,采用概率法合成了含有氨基、羧基的2种不对称酞菁锌(A3B).     

二茂铁取代卟啉的合成表征及电化学性质

通过吡咯与二茂铁甲醛和对甲基苯甲醛的直接交叉缩合反应,合成并成功分离了6个含有0~4个二茂铁取代基的卟啉化合物:5,10,15,20-四(4-甲苯基)卟啉[(CH3Ph)4PH2]、5-(二茂铁基)-10,15,20-三(4-甲苯基)卟啉[Fc(CH3Ph)3PH2]、cis-5,10-二(二茂铁基)-15,20-二(4-甲苯基)卟啉[cis-Fc2(CH3Ph)2PH2]、trans-5,15-二(二茂铁基)-10,20-二(4-甲苯基)卟啉[trans-Fc2(CH3Ph)2PH2]、5,10,15-三(二茂铁基)-20-(4-甲苯基)卟啉[Fc3(CH3Ph)PH2]、5,10,15,20-四(二茂铁基)卟啉[Fc4PH2]。用紫外-可见和红外光谱、核磁共振及质谱等技术对卟啉化合物进行了表征,用微量光谱滴定法测定了化合物在非水溶剂中的质子化反应常数,研究了它们的电化学和光谱电化学性质。结果表明,二茂铁取代基对化合物的光谱及氧化还原电位有较大的影响。     

Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection

A simple and sensitive high-performance liquid chromatography (HPLC) method was developed to quantitate imatinib in human plasma. Imatinib and the internal standard dasatinib were separated using a mobile phase of 0.5% KH(2)PO(4) (pH3.5)-acetonitrile-methanol (55:25:20, v/v/v) on a CAPCELL PAK C18 MG II column (250 mm × 4.6 mm) at a flow rate of 0.5 mL/min and measurement at UV 265 nm. Analysis required 100 μL of plasma and involved a solid phase extraction with an Oasis HLB cartridge, which gave recoveries of imatinib from 73% to 76%. The lower limit of quantification for imatinib was 10 ng/mL. The linear range of this assay was between 10 and 5000 ng/mL (regression line r(2) > 0.9992). Inter- and intra-day coefficients of variation were less than 11.9% and accuracies were within 8.3% over the linear range. The plasma concentrations of imatinib obtained by our present method were almost the same as those assayed by an LC-MS-MS method at the Toray Research Center, Inc. This method can be applied effectively to measure imatinib concentrations in clinical samples.     

Experimental design in reversed-phase high-performance liquid chromatographic analysis of imatinib mesylate and its impurity

For the determination of the optimal RP-HPLC chromatographic conditions for the separation of imatinib mesylate and its impurity STI 509-00 experimental design 2(4) was applied. All the factors that affect imatinib mesylate/STI 509-00 separation, as well as their mutual interactions were investigated. Methanol and triethylamine content in the mobile phase, pH of the mobile phase and column temperature were independent variables or factors to be investigated in two levels: "low" and "high". Capacity factor was chosen as a dependent variable. From the experimentally determined capacity factor values, it was defined the factors that affect to chromatographic system the most. Applying response surface methodology the appropriate graphs were constructed from experimental points and optimal chromatographic conditions for the separation were defined. Optimal conditions for the separation of imatinib mesylate and STI 509-00 were obtained using X Terra 150 mm x 4.6 mm, particle size 5 microm column at 25 degrees C. Mobile phase consisted of 250 ml of methanol, 740 ml of water and 10 ml of triehylamine. pH of water phase was adjusted to 2.4 with 85% orthophosphoric acid and then methanol was added.     

Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry

Imatinib is a first-line treatment for chronic myelogenous leukaemia (CML). The pharmacokinetics of imatinib in patients with CML are characterised by large interpatient variability. Concentration monitoring of imatinib and its active metabolite N-desmethyl imatinib (DMI) is considered necessary to enhance the safe and effective use of imatinib. A rapid, simple and sensitive liquid chromatography/tandem mass spectrometry assay was developed for the simultaneous determination of imatinib and its metabolite DMI in human plasma. After proteins were precipitated with acetonitrile, imatinib, DMI and the internal standard D8-imatinib were resolved on a Gemini-NX 3?μm C18 column using gradient elution of 0.05?% formic acid and methanol. The three compounds were detected using electrospray ionisation in the positive mode. Standard curves of imatinib and DMI were adequately fitted by quadratic equations (r?>?0.999) over the concentration range of 10 to 2,000?ng/mL which encompasses clinical concentrations. Bias was ≤±8.3?%, intra- and inter-day coefficients of variation (imprecision) were ≤8.0?% and the limit of quantification was 10?ng/mL for both imatinib and DMI. The assay is being used successfully in clinical practice to enhance the safe and effective use of imatinib.     

A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells

Multidrug resistance (MDR) is often associated with overexpression of the P-glycoprotein (P-gp, ABCB1). It was demonstrated that the P-gp mediated efflux decreases the drug concentration in cancer cells which results in the failure of chemotherapy. However, the MDR phenotype in cancer cells obviously involves various mechanisms. Therefore, if we want to estimate a contribution of the P-gp expression to the MDR phenotype, a clear quantitative relationship between the intracellular drug level and cell sensitivity must be established. To achieve this goal, a sensitive and non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite N-desmethyl imatinib (CGP 74588) has been developed. The assay is based on an optimised extraction of cells with 4% formic acid after their separation from the growth medium by centrifugation through a layer of silicone oil. Cell extracts are subsequently analyzed by LC/MS/MS. Calibration curves were linear from 1 to 500 nmol/l for imatinib and from 2 to 500 nmol/l for CGP 74588, with correlation coefficients (r²) better than 0.998 and 0.996, respectively. The limit of quantitation (LOQ) was 1 nmol/l for imatinib and 2 nmol/l for CGP 74588. Our method has been successfully applied to the determination of intracellular levels of imatinib in sensitive K562 and their resistant variant, K562/Dox cells.     

Crystal habit modifications of imatinib mesylate under various precipitation conditions

Abstract  

Crystals of the α-form of imatinib mesylate with various habits (e.g., polyhedral-like and plate-like) were prepared from various organic solvents (e.g., butyl lactate, 4-methyl-2-pentanone, 2-methyl-2-butanol, 2-isopropoxyethanol, propyl ether) by several precipitation methods. The methods provide imatinib mesylate in a non-needle-shaped crystalline α-form. The crystal modification was identified by hot-stage microscopy, scanning electron microscopy, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), and X-ray powder diffraction (XRPD). The analyses by DSC, IR, and XRPD indicate that imatinib mesylate crystals with various habits have the same crystal structure. The plate-like habit has been also observed in the system where the organic solvent acts as a precipitant.     

伊马替尼衍生物的合成及其抗肿瘤活性

以4-硝基-2-氨基甲苯为起始原料,经加成、缩合、环化和还原反应制得中间体N-(2-甲基-5-氨基苯基)-4-(3-吡啶基)嘧啶-2-胺(4),再与取代酰氯反应,合成了7个新型伊马替尼衍生物（5a~5g）,其结构经¹H NMR, ¹³C NMR和HR-MS 表征。采用四甲基偶氮唑盐(MTT)法考察了5对人肝癌细胞(HepG₂)、子宫颈癌细胞（Hela）、肺癌细胞（H460）和乳腺癌细胞（MCF-7）体外抑制活性。结果显示：5e体外抑制活性最优,其IC₅₀分别为10.90±1.00 μmol·L^-1; 8.51±0.90 μmol·L^-1; 13.15±1.11 μmol·L^-1; 14.75±0.78 μmol·L^-1。     

Influence of salt and acetonitrile on the capillary zone electrophoresis analysis of imatinib in plasma samples

A simple, sensitive, specific, and cost‐effective analytical methodology was developed for the analysis of human plasma samples spiked with imatinib by CZE with on‐line UV detection in the context of Therapeutic Drug Monitoring. Several analytical conditions such as the ionic strength (I) and the pH of the BGE composed of citric acid and ε‐amino caproic acid were studied in regards of the presence of sodium chloride (NaCl) in plasma samples (1% m/v). Computer simulations (Simul software) were used to confirm the experimental results and to understand imatinib electrophoretic behavior in the presence of NaCl. Furthermore, the advantages of adding ACN to the sample containing NaCl to combine efficient protein precipitation and on‐line CZE stacking of imatinib were demonstrated. LOD and LOQ values of 48 and 191 ng/mL were obtained from plasma sample supernatant after protein precipitation with ACN, which is much lower than mean imatinib plasma level observed for patients treated by imatinib mesylate (about 1000 ng/mL). Good linearity was obtained in the concentration range 191–5000 ng/mL (R² > 0.997). RSD of less than 1.68% and 2.60% (n = 6) for migration times and corrected peak areas, respectively, were observed at the LOQ.     

再生纤维素膜对聚苯乙烯的截留性

本文用铜氨法以及微相分离和后处理技术制备了孔径30A至1000A的一系列再生纤维素膜。采用膜渗透计按流动速率法及静态渗透压法分别测定了它们的平均孔径2rf以及膜在甲苯溶液中对聚苯乙烯标样的截留率Re。得到膜平均孔径和所截留聚苯乙烯分子最Mw及其均方根末端距〈h~2〉~(1/2)之间的关系式分别为: lg2r?=lg0.155 0.59lgM_w lg2rf=lg0.589 0.96lg〈h~2〉~(1/2)     

Nonaqueous capillary electrophoresis of imatinib mesylate and related substances

In the present study, nonaqueous capillary electrophoretic separation of imatinib mesylate (IM) and related substances, N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine (PYA), N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((piperazin-1-yl)methyl) benzamide (NDI) and 4-chloromethyl-N-(4-methyl-3-((4-(pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) benzamide (CPB) was developed. The influential factors affecting separation, including type and concentration of the electrolyte, applied voltage, and buffer modifier were investigated. Baseline separation of the studied analytes was obtained using a buffer of 50 mM Tris and 50 mM methanesulfonic acid in methanol at a apparent pH (pH*) of 1.65. To enhance the sensitivity, large-volume sample stacking was employed for online concentration. The strongest analytical signal with a suitable separation was achieved when the injection time was 100 s. The linearity ranges of PYA and NDI were 0.100-2.50 μg mL(-1) , and that of CPB was 0.125-2.50 μg mL(-1) , with good coefficients (r(2) > 0.9948). The relative standard deviations of intra- and interday were satisfactory. Under the optimized conditions, seven batches of the synthesized samples were analyzed and CPB was detected in two batches. Owing to its simplicity, effectiveness, and low price, the developed method is promising for quality control of IM.     

Thermosensitive molecularly imprinted poly(1‐vinyl‐2‐pyrrolidone/methyl methacrylate/N‐vinylcaprolactam) for selective extraction of imatinib mesylate in human biological fluid

The efficiency of a molecularly imprinted polymer as a selective packing material for the solid‐phase extraction of imatinib mesylate sorption was investigated. The molecularly imprinted polymer was prepared using N,N′‐methylenebisacrylamide as a cross‐linker agent, N‐vinylcaprolactam as a thermo‐sensitive monomer, 1‐vinyl‐2‐pyrrolidone and methyl methacrylate as functional monomers, azobisisobutyronitrile as an initiator and imatinib mesylate as a template. The drug‐imprinted polymer was identified by Fourier transform infrared spectroscopy, thermogravimetric analysis, elemental analysis, and scanning electron microscopy. It was found that this polymer can be used for determination of trace levels of imatinib mesylate with a recovery percentage that could reach over 90%. Furthermore, the synthesized molecularly imprinted polymer indicated higher selectivity towards imatinib mesylate than other compounds. From isotherm study, the equilibrium adsorption data of imatinib mesylate by imprinted polymer were analyzed by Langmuir, Freundlich, and Temkin isotherm models. The developed method was used for determination of imatinib mesylate in human fluid samples by high performance liquid chromatography with excellent results.